Subject(s)
Infliximab , Leishmaniasis, Visceral , Lymphohistiocytosis, Hemophagocytic , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Bone Marrow Examination/methods , Dexamethasone/administration & dosage , Fatal Outcome , Humans , Immunoglobulins, Intravenous/administration & dosage , Infliximab/administration & dosage , Infliximab/adverse effects , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/etiology , Leishmaniasis, Visceral/immunology , Leishmaniasis, Visceral/physiopathology , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/physiopathology , Lymphohistiocytosis, Hemophagocytic/therapy , Male , Patient Care Management/methods , Sarcoidosis/drug therapyABSTRACT
INTRODUCTION AND HYPOTHESIS: Cell-based tissue engineering strategies could potentially provide attractive alternatives to surgical reconstruction of native tissue or the use of surgical implants in treating pelvic organ prolapse (POP). METHODS: Based on a search in PubMed, this review focuses on candidate cell types, scaffolds, and trophic factors used in studies examining cell-based tissue engineering strategies to treat POP, stress urinary incontinence (SUI), and the closely related field of hernias. RESULTS: In contrast to the field of SUI, the use of cell-based tissue engineering strategies to treat POP are very sparsely explored, and only preclinical studies exist. CONCLUSION: The available evidence suggests that the use of autologous muscle-derived cells, fibroblasts, or mesenchymal stem cells seeded on biocompatible, degradable, and potentially growth-promoting scaffolds could be an alternative to surgical reconstruction of native tissue or the use of conventional implants in treating POP. However, the vagina is a complex organ with great demands of functionality, and the perfect match of scaffold, cell, and trophic factor has yet to be found and tested in preclinical studies. Important issues such as safety and economy must also be addressed before this approach is ready for clinical studies.
